Sino Biopharmaceutical Limited
SBHMY
Other OTC12.49
USD
-1.80
- -
ISIN
US82937X1037
CUSIP
82937X103
Return %
Stock
S&P500
1Y
31.70
26.53
3Y
34.68
76.60
5Y
-44.19
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- S. Y. Tse
- Full Time Employees
- 24,379
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Office Tower Wan Chai Hong Kong
- IPO Date
- Sep 5, 2017
- Website
- sinobiopharm.com
- Similar Companies
- Business
- Sino Biopharmaceutical Limited (HKEX: 1177; OTC: SBHMY) is a leading research-driven pharmaceutical company focused on the research, development, manufacture and marketing of innovative biopharmaceutical and chemical medicines across oncology, surgery/analgesia, hepatitis, respiratory system, cardio-cerebral vascular and other therapeutic areas. Founded in 1995 and headquartered in Hong Kong with principal operations in mainland China including facilities in Beijing, Lianyungang and Nanjing, the company operates primarily in China and pursues global expansion through partnerships and acquisitions. Its core products include oncology medicines such as Focus V (Anlotinib Hydrochloride) capsules, Annike (Penpulimab) injection, Qingkeshu (Abiraterone Acetate) tablets, Zewanxin (Lenvatinib Mesilate) capsules and Anxian (Lenalidomide) capsules; surgery/analgesia medicines such as Debaian (Flurbiprofen Cataplasms), Gaisanchun (Calcitriol) soft capsules and Chia Tai Jiuli (Glucosamine hydrochloride) tablets; hepatitis medicines including Tianqing Ganmei (Magnesium Isoglycyrrhizinate) injection, Runzhong (Entecavir) dispersible tablets and Tianqing Ganping (Diammonium Glycyrrhizinate) enteric-coated capsules; respiratory medicines such as Tianqing Suchang (Budesonide) suspension for inhalation and Tianqing Sule (Tiotropium Bromide) powder for inhalation; cardio-cerebral vascular medicines like Yilunping (Irbesartan and Hydrochlorothiazide) tablets and Tuotuo (Rosuvastatin Calcium) tablets; as well as others including Taibowei (Adalimumab) injection and Aisuping (Omeprazole) enteric-coated capsules. Oncology accounts for around 37% of revenue, with innovative products comprising 42% of total sales in recent periods. Recent developments include the July 2025 completion of invoX Pharma's $161 million acquisition of F-star Therapeutics, enhancing its bispecific antibody capabilities in immunotherapy following U.S. regulatory clearance; the July 2025 agreement to acquire the remaining 95% stake in LaNova Medicines for up to $951 million (net $501 million after cash), integrating advanced oncology assets like PD-1xVEGF bispecific LM-299 (licensed to Merck), GPRC5D ADC LM-305 (licensed to AstraZeneca), Claudin 18.2 ADC in phase 3 and CCR8 antibody in phase 2, bolstering antibody platforms in tumor microenvironment, ADCs and T-cell engagers; NMPA approval in February 2025 for Limaprost tablet (Kailitong) targeting lumbar spinal stenosis affecting over 30 million patients; CDE acceptance of clinical trial application for innovative Claudin18.2 ADC TQB2103; and plans to establish a Guangzhou innovation center as southern headquarters. The company maintains a robust R&D pipeline with over 40 oncology candidates and invests heavily in innovation, positioning it as a top player in China's pharmaceutical sector with products distributed domestically and internationally.
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day